Mindprint implements market-leading automation solution for Ockham Oncology

Mindprint Inc. and Ockham Development, Inc. have implemented an innovative automation software system to help the global CRO manage trials efficiently to ensure a more focused approach to its core oncology mission.

Mindprint, a Toronto-based company specializing in software management solutions for the Contract Research industry, has worked onsite with Ockham to customize the new management tool, which went live in December 2013.

"Our passion is helping companies fight cancer," said Jim Baker, CEO of Ockham, which includes a global division solely focused on cancer drug trials. "We have successfully completed more than 250 oncology trials for some of the leading pharma companies.

"Because of the operational complexity in managing global trials, our conventional software tools have become cumbersome. After extensive research, we chose Mindprint as our solution."

Ockham continues to experience fast growth just two years after the successful integration of Nexus Oncology a Scotland-based oncology CRO. Mindprint, which specializes in CRO software solutions, prepared an operational plan while working closely with the Ockham team.

"We interviewed the key subject matter experts for Ockham Oncology," said Prasad A. Sristi, CEO of Mindprint."We were able to use our library of CRO solutions for demo purposes to gather quality feedback and build consensus about what Ockham needed." Both Sristi and Baker praised the thorough review of Ockham's business.

"These new tools help us serve our clients more effectively and preserve our essential focus on the clinical challenge in helping our clients in developing new cancer-fighting formulations," Baker said.

Mindprint implemented a professional services automation (PSA) tool customized for Ockham's needs. A key part of the PSA allows Ockham to measure the profitability of each clinical study - a challenging aspect of every trial due to the many data sources associated with each trial.

Sristi said the core of the technology is the patented Axpert platform developed in Bangalore by India-based Agile Labs. This tool allow the customization of enterprise management systems without extensive hard coding.

Baker praised Mindprint software's capacity to do much more for their business in addition to generating interactive reports on profitability. "The system implemented by Mindprint is exactly what we needed," Baker said. "When we began implementation, we realized that if utilized correctly Mindprint can be fundamental to our business and meet our growth demands."

The new software tools allow "much more accurate financial data and financial forecasts for our entire company," Baker said.

About Ockham
Launched in 1986, Ockham is a global oncology CRO and full-spectrum global resourcing company. Clinical expertise, therapeutic focus, and successful oncology trial outcomes have created an industry leadership position for Ockham Oncology. Ockham Source continues to achieve sustained success by offering traditional sourcing solutions as well as a growing FSP (Functional Service Provider). Ockham’s world headquarters is based in Cary, North Carolina, with the European headquarters located in Roslin, Scotland, near Edinburgh. Ockham offices are located strategically around the world to serve global customers.

About Mindprint
Mindprint Inc. specializes in serving Contract Research Organizations and pharmaceutical companies with cloud-based enterprise software solutions that provide direct business benefits such as enhanced profitability, streamlined business processes and superior customer value. Launched in 2009 and headquartered in Markham, Ontario, Mindprint has partnered with a number of leading CROs and understands the life cycle of a clinical study as well as the business challenges and system requirements unique to the life sciences industry. Mindprint's library of CRO modules, based on the Axpert enterprise resource planning platform enables rapid custom software development without expensive coding. Read more about Mindprint Inc.

Most Popular Now

ACE2 protein protects against severe COVID-19

Female COVID-19 patients face less severe disease complications and a lower risk of dying than male patients thanks to hormones and chromosomes that contribute to a stron...

Neutralizing antibodies protect against severe COV…

Understanding the body's immune response to SARS-CoV-2, the virus that causes COVID-19, is key to developing effective treatments and long-lasting vaccines. Of particular...

How SARS-CoV-2 interacts with cells

SARS-CoV-2 infections pose a global threat to human health and a formidable research challenge. One of the most urgent tasks is to gain a detailed understanding of the mo...

Sustained cellular immune dysregulation in individ…

COVID-19, which has killed 1.7 million people worldwide, does not follow a uniform path. Many infected patients remain asymptomatic or have mild symptoms. Others, espe...

Vir Biotechnology and GSK announce start of NIH-sp…

Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that the first patient has been dosed in a new sub-trial of the National Ins...

Pfizer and BioNTech to supply the U.S. with 100 mi…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced a second agreement with the U.S. government to supply an additional 100 million doses of the compan...

Pfizer and BioNTech receive CHMP positive opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EM...

Pfizer and BioNTech receive authorization in the E…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the European Commission (EC) has granted a conditional marketing authorization (CMA) to Pfizer...

New virtual screening strategy identifies existing…

A novel computational drug screening strategy combined with lab experiments suggest that pralatrexate, a chemotherapy medication originally developed to treat lymphoma, c...

Novavax announces initiation of PREVENT-19 pivotal…

Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced initiation of PREVEN...

Serum Institute of India obtains emergency use aut…

AstraZeneca's COVID-19 vaccine has been granted emergency use authorisation in India as well as Argentina, Dominican Republic, El Salvador, Mexico and Morocco for the act...

China grants conditional market approval for Sinop…

The inactivated COVID-19 vaccine developed by Beijing Institute of Biological Products of Sinopharm CNBG has been granted conditional registration by the NMPA of China, C...